Cronus Pharma LLC, a leader in animal health innovation, is excited to announce the release of its new Pimobendan Chewable Tablets, the first FDA-approved bioequivalent of Vetmedin®.
Cronus Pharma LLC, a leader in animal health innovation, announced the launch / release of its new Pimobendan Chewable Tablets, available for purchase in the U.S. veterinary market after June 9, 2026. This is the first generic Pimobendan product available in USA, and is designed to support veterinarians in providing high-quality cardiac care for dogs. It is the first FDA-approved bioequivalent of Vetmedin®.
About Pimobendan Chewable Tablets
-
Indicated for the management of mild, moderate, or severe congestive heart failure in dogs due to myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM).
-
Proven results from rigorous FDA-approved studies and consistent manufacturing standards, compared to unapproved compounded versions.
-
Suitable for use with concurrent congestive heart failure therapies (e.g., furosemide) as appropriate on a case-by-case basis.
-
Supplied as oblong half-scored chewable tablets in four strengths: 1.25 mg, 2.5 mg, 5 mg, and 10 mg pimobendan per tablet – 50 tablets per bottle.
-
Approved by the FDA under ANADA # 200-728.
About Cronus Pharma
Based in East Brunswick, New Jersey, Cronus Pharma is a privately held veterinary generic pharmaceutical company dedicated to advancing animal health. With integrated research, development, manufacturing, and marketing, we deliver innovative and cost-effective solutions for companion animals. Our passionate team of scientists is actively developing new products, with several awaiting FDA approval. Cronus Pharma is committed to supporting veterinarians and pet owners with high-quality, accessible solutions.
Learn more about Cronus Animal Health at www.cronuspharmausa.com.
Vetmedin® is a trademark of Boehringer Ingelheim Animal Health.
